News

2017 News Releases

Keyword Search
 
2017 | 2016
DateTitle 
05/23/17Aralez to present at the Jefferies Healthcare Conference
MISSISSAUGA, Ontario, May 23, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the Jefferies Healthcare Conference to be held June 6-9, 2017 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 8:30 a.m. local time on Wednesday, June 7, 2017. A live webcast and audio archive for the event may be accessed from the Investors... 
Printer Friendly Version
05/09/17Aralez Reports First Quarter 2017 Financial Results
-First Quarter 2017 Net Revenues of $26.0 Million- -Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance- -Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month- MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The ... 
Printer Friendly Version
05/03/17Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders
MISSISSAUGA, Ontario, May 3, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2017 annual and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.  The total number of common shares of the Company ("Common Shares") represented by Shareholders present in ... 
Printer Friendly Version
04/25/17Aralez To Report First Quarter 2017 Financial Results On May 9, 2017
-Executive Management to Host Conference Call on May 9, 2017 at 9:00 a.m. ET- MISSISSAUGA, Ontario, April 25, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its first quarter 2017 financial results on Tuesday, May 9, 2017, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 9:00 a.m. ET on such date to discuss the Company's financial res... 
Printer Friendly Version
04/05/17Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program
-32% Reduction in the U.S. Sales Force- -Strategic Realignment of Resources with an Emphasis on the Zontivity® Launch- -Support Yosprala® with Direct Selling Efforts Only- -Company Commences Spend Reductions Across Business- MISSISSAUGA, Ontario, April 5, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has begun implementing a program of cost savings initiatives with the immediate aim of providing addition... 
Printer Friendly Version
03/20/17Aralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market
MISSISSAUGA, Ontario, March 20, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that Adrian Adams, the Chief Executive Officer of the Company, acquired an additional 500,000 shares of the Company's common stock on March 15, 2017 in open-market purchases. The shares were purchased at an average price of $2.46 per share, for an aggregate purchase price of approximately $1,230,000. Following this transaction, Mr. Adams owns 3,56... 
Printer Friendly Version
03/13/17Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results
-4Q16 Net Revenues Increased to $20 Million Versus $6 Million in the Comparable Period of 2015- -Full-Year Net Revenues Increased to $54.3 Million Versus $21.4 Million in the Comparable Period of 2015- -Provides 2017 Full-Year Guidance- MISSISSAUGA, Ontario, March 13, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the fourth quarter and full-year ended December 31, 2016. The Company also highli... 
Printer Friendly Version
02/27/17Aralez To Announce Fourth Quarter And Full-Year 2016 Results On March 13, 2017
-Executive Management to Host Conference Call on March 13, 2017 at 9:00 a.m. ET- MISSISSAUGA, Ontario, Feb. 27, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its 2016 fourth quarter and full-year financial results on Monday, March 13, 2017, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 9:00 a.m. ET on such date to discuss the... 
Printer Friendly Version
02/16/17Aralez to Present at the RBC Capital Markets Global Healthcare Conference
MISSISSAUGA, Ontario, Feb. 16, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the RBC Capital Markets Global Healthcare Conference to be held February 22-23, 2017. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:35 p.m. local time on Wednesday, February 22, 2017. A live webcast and audio archive for the event may be accessed ... 
Printer Friendly Version
02/13/17Aralez To Ring Closing Bell At Nasdaq On February 14, 2017
MISSISSAUGA, Ontario, Feb. 13, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 14, 2017 to celebrate its commitment to cardiovascular disease and the commercial launch of Yosprala®. Chief Executive Officer, Adrian Adams, will perform the honorary bell ringing ceremony that w... 
Printer Friendly Version
02/02/17Aralez Pharmaceuticals unveils new office in Ireland
... 
Printer Friendly Version
01/11/17Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
MISSISSAUGA, Ontario, Jan. 11, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omepra... 
Printer Friendly Version
01/09/17Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate, PA10040, for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. "As we seek to maximize the opportunity for Yosprala on a worldwide basis, we plan to e... 
Printer Friendly Version
01/09/17Aralez Provides Update On PBM Formulary Status For Yosprala
-Secures Formulary Status with Express Scripts Inc. for Yosprala™- MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has entered into a rebate agreement with Express Scripts Inc., which secures formulary status for Yosprala™, the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and a proton pump inhibitor, omeprazole, in the United States. The rebate agreement... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.